WVE
Wave Life Sciences Ltd.
Price Chart
Latest Quote
$13.43
Current Price| Previous Close | $12.94 |
| Open | $12.69 |
| Day High | $13.57 |
| Day Low | $12.69 |
| Volume | 2,541,832 |
Stock Information
| Shares Outstanding | 185.76M |
| Total Debt | $19.77M |
| Cash Equivalents | $196.22M |
| Revenue | $109.23M |
| Net Income | $-121.95M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $2.49B |
| EPS (TTM) | $-0.65 |
| Exchange | NGM |
📊 Custom Metrics & Score
Score: 22/42| Debt to Equity | 0.12 |
| Debt to Earnings | -0.26 |
| Current Ratio | 2.89 |
| Quick Ratio | 2.74 |
| Avg Revenue Growth | 41.10% |
| Profit Margin | -89.57% |
| Return on Equity | -46.30% |
| Avg FCF Growth | 17.42% |
| FCF Yield | -6.09% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $13.43 | 2,543,800 |
| 2026-01-30 | $12.94 | 2,327,900 |
| 2026-01-29 | $13.01 | 3,564,900 |
| 2026-01-28 | $12.73 | 13,122,100 |
| 2026-01-27 | $13.36 | 3,607,700 |
| 2026-01-26 | $13.25 | 1,660,100 |
| 2026-01-23 | $13.47 | 2,244,400 |
| 2026-01-22 | $13.82 | 3,444,700 |
| 2026-01-21 | $13.94 | 2,438,400 |
| 2026-01-20 | $13.82 | 2,980,800 |
| 2026-01-16 | $13.65 | 3,702,000 |
| 2026-01-15 | $14.07 | 2,841,900 |
| 2026-01-14 | $14.51 | 6,073,700 |
| 2026-01-13 | $14.22 | 4,232,700 |
| 2026-01-12 | $13.91 | 6,145,700 |
| 2026-01-09 | $13.84 | 3,747,000 |
| 2026-01-08 | $14.83 | 3,152,100 |
| 2026-01-07 | $15.43 | 5,938,800 |
| 2026-01-06 | $15.15 | 15,042,400 |
| 2026-01-05 | $15.00 | 4,949,500 |
About Wave Life Sciences Ltd.
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-N531, an exon skipping oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
📰 Latest News
GSK walks away from pioneering Wave RNA editing drug
BioPharma Dive • 2026-02-02T08:31:00Z
Should Wave’s New Obesity Data and INHBE/ALK7 Focus Require Action From Wave Life Sciences (WVE) Investors?
Simply Wall St. • 2026-01-19T03:11:33Z
This Director Sold 42,000 Shares of Wave Life Sciences for $630,000. What Investors Should Know About This Biotech Company.
Motley Fool • 2026-01-14T13:38:50Z
Arrowhead Says Its Gene Silencer Doubled Zepbound's Weight Loss
Investor's Business Daily • 2026-01-06T21:28:14Z
Zepbound Boost Gets a Lift From Arrowhead’s Drug. The Question Is Whether Patients Will Pay.
Barrons.com • 2026-01-06T16:26:00Z
Assessing Wave Life Sciences (WVE) Valuation After A Sharp Share Price Rebound
Simply Wall St. • 2026-01-06T14:09:35Z
Three Genomics Stocks Worth Tracking This Year
Zacks • 2026-01-06T12:06:00Z
Wave Life Sciences (WVE) Emerges as Obesity Treatment Contender, Oppenheimer Boosts Price Target
Insider Monkey • 2026-01-02T15:50:44Z
Wave Life Sciences’ (WVE) RNA Obesity Drug WVE-007 Shows Potential to Match GLP-1 Efficacy Without Muscle Loss
Insider Monkey • 2025-12-31T16:25:22Z
H.C. Wainwright Maintains A Buy Rating On Wave Life Sciences Ltd. (WVE)
Insider Monkey • 2025-12-31T04:46:40Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | $108,302,000 | $113,305,000 | $3,649,000 | $40,964,000 |
| Operating Revenue | $108,302,000 | $113,305,000 | $3,649,000 | $40,964,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Expenses | $218,705,000 | $181,301,000 | $166,369,000 | $167,980,000 |
| Other Income Expense | $13,395,000 | $9,806,000 | $1,578,000 | $4,567,000 |
| Other Non Operating Income Expenses | $3,232,000 | $1,878,000 | $7,000 | $4,537,000 |
| Operating Expense | $218,705,000 | $181,301,000 | $166,369,000 | $167,980,000 |
| General And Administrative Expense | $59,023,000 | $51,292,000 | $50,513,000 | $46,105,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-97,008,000 | $-57,513,000 | $-161,823,000 | $-122,245,000 |
| Normalized Income | $-107,171,000 | $-65,345,864 | $-163,126,930 | $-122,274,940 |
| Net Income From Continuing And Discontinued Operation | $-97,008,000 | $-57,513,000 | $-161,823,000 | $-122,245,000 |
| Total Operating Income As Reported | $-110,403,000 | $-67,996,000 | $-162,720,000 | $-127,016,000 |
| Net Income Common Stockholders | $-97,008,000 | $-57,513,000 | $-161,823,000 | $-122,245,000 |
| Net Income | $-97,008,000 | $-57,513,000 | $-161,823,000 | $-122,245,000 |
| Net Income Including Noncontrolling Interests | $-97,008,000 | $-57,513,000 | $-161,823,000 | $-122,245,000 |
| Net Income Continuous Operations | $-97,008,000 | $-57,513,000 | $-161,823,000 | $-122,245,000 |
| Pretax Income | $-97,008,000 | $-58,190,000 | $-161,142,000 | $-122,449,000 |
| Operating Income | $-110,403,000 | $-67,996,000 | $-162,720,000 | $-127,016,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-0.70 | $-0.54 | $-2.05 | $-2.36 |
| Basic EPS | $-0.70 | $-0.54 | $-2.05 | $-2.36 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $95,136 | $267,070 | $60 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-111,903,000 | $-66,718,000 | $-154,177,000 | $-117,211,000 |
| Total Unusual Items | $10,163,000 | $7,928,000 | $1,571,000 | $30,000 |
| Total Unusual Items Excluding Goodwill | $10,163,000 | $7,928,000 | $1,571,000 | $30,000 |
| Reconciled Depreciation | $8,663,000 | $9,206,000 | $10,114,000 | $9,835,000 |
| EBITDA (Bullshit earnings) | $-101,740,000 | $-58,790,000 | $-152,606,000 | $-117,181,000 |
| EBIT | $-110,403,000 | $-67,996,000 | $-162,720,000 | $-127,016,000 |
| Diluted Average Shares | $138,277,468 | $106,097,268 | $78,855,810 | $51,825,566 |
| Basic Average Shares | $138,277,468 | $106,097,268 | $78,855,810 | $51,825,566 |
| Diluted NI Availto Com Stockholders | $-97,008,000 | $-57,513,000 | $-161,823,000 | $-122,245,000 |
| Tax Provision | $0 | $-677,000 | $681,000 | $-204,000 |
| Gain On Sale Of Security | $10,163,000 | $7,928,000 | $1,571,000 | $30,000 |
| Research And Development | $159,682,000 | $130,009,000 | $115,856,000 | $121,875,000 |
| Selling General And Administration | $59,023,000 | $51,292,000 | $50,513,000 | $46,105,000 |
| Other Gand A | $59,023,000 | $51,292,000 | $50,513,000 | $46,105,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $209,515,000 | $39,630,000 | $-45,091,000 | $32,498,000 |
| Total Assets | $352,207,000 | $274,949,000 | $146,386,000 | $207,007,000 |
| Total Non Current Assets | $31,813,000 | $39,576,000 | $47,849,000 | $44,443,000 |
| Other Non Current Assets | $3,815,000 | $3,855,000 | $3,722,000 | $3,799,000 |
| Current Assets | $320,394,000 | $235,373,000 | $98,537,000 | $162,564,000 |
| Other Current Assets | $7,350,000 | $4,024,000 | $2,108,000 | $5,416,000 |
| Prepaid Assets | $9,544,000 | $9,912,000 | $7,932,000 | $6,584,000 |
| Receivables | $1,422,000 | $21,086,000 | $0 | $0 |
| Accounts Receivable | $1,422,000 | $21,086,000 | $0 | $0 |
| Cash Cash Equivalents And Short Term Investments | $302,078,000 | $200,351,000 | $88,497,000 | $150,564,000 |
| Cash And Cash Equivalents | $302,078,000 | $200,351,000 | $88,497,000 | $150,564,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $25,404,000 | $32,118,000 | $37,614,000 | $29,916,000 |
| Long Term Debt And Capital Lease Obligation | $17,766,000 | $25,404,000 | $32,118,000 | $24,955,000 |
| Current Debt And Capital Lease Obligation | $7,638,000 | $6,714,000 | $5,496,000 | $4,961,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $142,692,000 | $235,319,000 | $191,477,000 | $174,509,000 |
| Total Non Current Liabilities Net Minority Interest | $31,739,000 | $48,879,000 | $119,956,000 | $110,308,000 |
| Non Current Deferred Liabilities | $6,099,000 | $15,601,000 | $79,774,000 | $77,479,000 |
| Current Liabilities | $110,953,000 | $186,440,000 | $71,521,000 | $64,201,000 |
| Current Deferred Liabilities | $65,972,000 | $150,059,000 | $31,558,000 | $37,098,000 |
| Payables And Accrued Expenses | $21,985,000 | $15,602,000 | $22,180,000 | $11,961,000 |
| Payables | $16,262,000 | $12,839,000 | $16,915,000 | $7,281,000 |
| Accounts Payable | $16,262,000 | $12,839,000 | $16,915,000 | $7,281,000 |
| Other Non Current Liabilities | - | - | $190,000 | - |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $209,515,000 | $39,630,000 | $-45,091,000 | $32,498,000 |
| Total Equity Gross Minority Interest | $209,515,000 | $39,630,000 | $-45,091,000 | $32,498,000 |
| Stockholders Equity | $209,515,000 | $39,630,000 | $-45,091,000 | $32,498,000 |
| Gains Losses Not Affecting Retained Earnings | $-262,000 | $-124,000 | $-29,000 | $181,000 |
| Other Equity Adjustments | $-262,000 | $-124,000 | $-29,000 | $181,000 |
| Retained Earnings | $-1,121,858,000 | $-1,024,850,000 | $-967,337,000 | $-805,514,000 |
| Preferred Securities Outside Stock Equity | $7,874,000 | $7,874,000 | $7,874,000 | $7,874,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $153,037,286 | $119,162,234 | $86,924,643 | $59,841,116 |
| Share Issued | $153,037,286 | $119,162,234 | $86,924,643 | $59,841,116 |
| Tangible Book Value | $209,515,000 | $39,630,000 | $-45,091,000 | $32,498,000 |
| Invested Capital | $209,515,000 | $39,630,000 | $-45,091,000 | $32,498,000 |
| Working Capital | $209,441,000 | $48,933,000 | $27,016,000 | $98,363,000 |
| Capital Lease Obligations | $25,404,000 | $32,118,000 | $37,614,000 | $29,916,000 |
| Total Capitalization | $209,515,000 | $39,630,000 | $-45,091,000 | $32,498,000 |
| Additional Paid In Capital | $156,454,000 | $129,237,000 | $119,442,000 | $87,980,000 |
| Capital Stock | $1,175,181,000 | $935,367,000 | $802,833,000 | $749,851,000 |
| Common Stock | $1,175,181,000 | $935,367,000 | $802,833,000 | $749,851,000 |
| Non Current Deferred Revenue | $6,099,000 | $15,601,000 | $79,774,000 | $77,479,000 |
| Long Term Capital Lease Obligation | $17,766,000 | $25,404,000 | $32,118,000 | $24,955,000 |
| Current Deferred Revenue | $65,972,000 | $150,059,000 | $31,558,000 | $37,098,000 |
| Current Capital Lease Obligation | $7,638,000 | $6,714,000 | $5,496,000 | $4,961,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $15,358,000 | $14,065,000 | $12,287,000 | $10,181,000 |
| Current Accrued Expenses | $5,723,000 | $2,763,000 | $5,265,000 | $4,680,000 |
| Net PPE | $27,998,000 | $35,721,000 | $44,127,000 | $40,644,000 |
| Accumulated Depreciation | $-46,329,000 | $-42,709,000 | $-37,846,000 | $-32,230,000 |
| Gross PPE | $74,327,000 | $78,430,000 | $81,973,000 | $72,874,000 |
| Leases | $28,885,000 | $28,525,000 | $28,413,000 | $27,994,000 |
| Construction In Progress | $349,000 | $294,000 | $318,000 | $28,000 |
| Other Properties | $17,870,000 | $22,637,000 | $26,843,000 | $18,378,000 |
| Machinery Furniture Equipment | $27,223,000 | $26,974,000 | $26,399,000 | $26,474,000 |
| Properties | $0 | $0 | $0 | $0 |
| Treasury Shares Number | - | $0 | - | - |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-151,964,000 | $-20,546,000 | $-129,142,000 | $-89,553,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-151,026,000 | $-19,431,000 | $-127,781,000 | $-88,993,000 |
| Cash Flow From Continuing Operating Activities | $-151,026,000 | $-19,431,000 | $-127,781,000 | $-88,993,000 |
| Operating Gains Losses | - | - | $12,000 | - |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-938,000 | $-1,115,000 | $-1,361,000 | $-560,000 |
| Investing Cash Flow | $-938,000 | $-1,115,000 | $-1,255,000 | $-560,000 |
| Cash Flow From Continuing Investing Activities | $-938,000 | $-1,115,000 | $-1,255,000 | $-560,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Issuance Of Capital Stock | $236,176,000 | $131,277,000 | $52,325,000 | $54,970,000 |
| Financing Cash Flow | $253,890,000 | $132,534,000 | $67,188,000 | $55,828,000 |
| Cash Flow From Continuing Financing Activities | $253,890,000 | $132,534,000 | $67,188,000 | $55,828,000 |
| Net Common Stock Issuance | $236,176,000 | $131,277,000 | $52,325,000 | $54,970,000 |
| Common Stock Issuance | $236,176,000 | $131,277,000 | $52,325,000 | $54,970,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| End Cash Position | $305,838,000 | $204,050,000 | $92,157,000 | $154,215,000 |
| Beginning Cash Position | $204,050,000 | $92,157,000 | $154,215,000 | $188,148,000 |
| Effect Of Exchange Rate Changes | $-138,000 | $-95,000 | $-210,000 | $-208,000 |
| Changes In Cash | $101,926,000 | $111,988,000 | $-61,848,000 | $-33,725,000 |
| Proceeds From Stock Option Exercised | $17,714,000 | $1,257,000 | $14,863,000 | $858,000 |
| Net Investment Purchase And Sale | $0 | $0 | $0 | $0 |
| Sale Of Investment | $0 | $0 | $75,044,000 | $0 |
| Purchase Of Investment | $0 | $0 | $-75,044,000 | $0 |
| Net PPE Purchase And Sale | $-938,000 | $-1,115,000 | $-1,255,000 | $-560,000 |
| Sale Of PPE | $0 | $0 | $106,000 | $0 |
| Purchase Of PPE | $-938,000 | $-1,115,000 | $-1,361,000 | $-560,000 |
| Change In Working Capital | $-75,822,000 | $19,081,000 | $6,722,000 | $7,010,000 |
| Change In Other Working Capital | $-93,589,000 | $54,328,000 | $-3,245,000 | $-18,464,000 |
| Change In Other Current Liabilities | $-6,714,000 | $-5,686,000 | $-4,118,000 | $-4,361,000 |
| Change In Other Current Assets | $-3,225,000 | $-2,010,000 | $3,394,000 | $-338,000 |
| Change In Payables And Accrued Expense | $7,674,000 | $-4,485,000 | $12,039,000 | $-3,677,000 |
| Change In Accrued Expense | $4,253,000 | $-724,000 | $2,691,000 | $2,890,000 |
| Change In Payable | $3,421,000 | $-3,761,000 | $9,348,000 | $-6,567,000 |
| Change In Account Payable | $3,421,000 | $-3,761,000 | $9,348,000 | $-6,567,000 |
| Change In Prepaid Assets | $368,000 | $-1,980,000 | $-1,348,000 | $3,850,000 |
| Change In Receivables | $19,664,000 | $-21,086,000 | $0 | $30,000,000 |
| Changes In Account Receivables | $19,664,000 | $-21,086,000 | $0 | $30,000,000 |
| Stock Based Compensation | $13,141,000 | $9,795,000 | $17,194,000 | $16,407,000 |
| Depreciation Amortization Depletion | $8,663,000 | $9,206,000 | $10,114,000 | $9,835,000 |
| Depreciation And Amortization | $8,663,000 | $9,206,000 | $10,114,000 | $9,835,000 |
| Depreciation | $8,663,000 | $9,206,000 | $10,114,000 | $9,835,000 |
| Gain Loss On Sale Of PPE | $0 | $0 | $12,000 | $0 |
| Net Income From Continuing Operations | $-97,008,000 | $-57,513,000 | $-161,823,000 | $-122,245,000 |